ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2025
[The EMBARK trial: The use of enzalutamide in biochemically recurrent prostate cancer after primary therapy].
Mohamed Shelan et al.PubMed ↗Publisher ↗
No numbers read from the abstract.